| Final Impact of Anti-Vascular Endothelial Growth Factor Treatment in Age-related Macular Degeneration. |
|
Jangmi Yang, Sang Jin Shin, Jae Kyung Suh, Songhee Cho, Hajin Tchoe, Min Joo Kang, Donghyun Jee |
1Office of Economic Evaluation Research, National Evidence Based Healthcare Collaborating Agency, Seoul, Korea.
2Department of Ophthalmology and Visual Science, St. Vincent Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. doj087@mail.catholic.ac.kr |
| 연령관련황반변성 환자에서 항혈관내피성장인자의 치료 방법과 재정 영향 분석 |
|
양장미1⋅신상진1⋅서재경1⋅조송희1⋅최하진1⋅강민주1⋅지동현2 |
|
한국보건의료연구원 경제성평가연구단1, 가톨릭대학교 의과대학 성빈센트병원 안과 및 시과학교실2 |
Correspondence:
Donghyun Jee,
Email: doj087@mail.catholic.ac.kr
|
|
Received: 3 May 2018 • Revised: 29 June 2018 • Accepted: 22 October 2018 |
| Abstract |
PURPOSE
To evaluate the effects of anti-vascular endothelial growth factor (VEGF) treatment on the healthcare-related finances of patients with age-related macular degeneration. METHODS: Changes in health care financing due to newly introduced benefit standards were predicted over the coming 5-year period (2018–2022). We also analyzed the financial impact of scenarios in which agents similar to anti-VEGF, such as the over-licensed drug bevacizumab, were introduced. For this purpose, the future number of patients receiving anti-VEGF treatments was estimated for various scenarios based on National Health Insurance Corporation claims data followed by an estimate of the financial burden. RESULTS: In the case of age-related macular degeneration, the current standard of care (14 times in a lifetime) was maintained in scenario 1. In 2018, the insurance budget for the coming 5-year period was estimated at approximately 440.3 billion won. The insurance cost for that period was estimated at approximately 560.1 billion won under the revised standard of December 2017 (scenario 2). For scenarios wherein, after 2020, similar treatments (scenario 3) and bevacizumab (scenario 4) were introduced, the estimated health insurance costs were 521 billion won and 419.7 billion won, respectively. CONCLUSIONS: Health insurance costs are projected to increase substantially due to the elimination of the 14 time pay standard; however, the actual budget will only moderately increase, due to new limitations of visual acuity ≤ 0.1 or in case of scarring/ atrophic lesions. Clinically similar agents and bevacizumab could be considered as alternatives to anti-VEGF treatment for age-related macular degeneration. |
| Key Words:
Age-related macular degeneration;Anti-vascular endothelial growth factor;Ranibizumab |
|
PDF Links
Full text via DOI
Download Citation
